News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Life Sciences Investor Forum on March 12, 2026. More about Jaguar's novel prescription drugs for gastrointestinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Jaguar Health, Inc. strengthens balance sheet by restructuring debt and royalty obligations. Sharp focus on global development program for crofelemer. CEO Lisa Conte prioritizes capitalization -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Jaguar Health, Inc. receives $16M non-dilutive capital from U.S. license agreement with Future Pak for crofelemer drugs. Strategy focuses on rare-disease intestinal failure indications -
